Suppression of HER-2 via siRNA interference promotes apoptosis and decreases metastatic potential of SKOV-3 human ovarian carcinoma cells

Oncology Reports

Volumn 29, Issue 3, 2013, Pages 1133-1139

  Lu, Yan Ming ^a   Rong, Meng Li ^a,b   Shang, Chao ^a   Wang, Ning ^a   Li, Xiang ^a   Zhao, Yan Yan ^a   Zhang, Shu Lan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b MACAO POLYTECHNIC INSTITUTE   (Macao)

Author keywords

Apoptosis; E cadherin; Epithelial mesenchymal transition; Human epidermal growth factor receptor 2; Invasion; Matrix metallopeptidase 9; Migration; Ovarian carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE B; NERVE CELL ADHESION MOLECULE; SMALL INTERFERING RNA; UVOMORULIN; VIMENTIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS POTENTIAL; NICK END LABELING; ONCOGENE NEU; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84872790160     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2214     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000. (Pubitemid 30428195)
4. Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459, 2005. (Pubitemid 47050835)
5. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001. (Pubitemid 33674041)
6. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005. (Pubitemid 40637826)
7. + advanced breast cancer patients receiving trastuzumab- containing therapy. Oncologist 17: 26-35, 2012.
8. Howe LR and Brown PH: Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res 4: 1149-1157, 2011.
9. Modjtahedi H and Essapen S: Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 20: 851-855, 2009.
10. Serrano-Olvera A, Dueñas-González A, Gallardo-Rincón D, Candelaria M and De la Garza-Salazar J: Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 32: 180-190, 2006.
11. Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M and Lloyd KO: Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol 168: 162-169, 1993. (Pubitemid 23047634)
12. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by stranded RNA in Caenorhabditis elegans. Nature 391: 806-811, 1998. (Pubitemid 28099681)
13. Szweykowska-Kulińska Z, Jarmołowski A and Figlerowicz M: RNA interference and its role in the regulation of eucaryotic gene expression. Acta Biochim Pol 50: 217-229, 2003. (Pubitemid 37034244)
14. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001. (Pubitemid 32494397)
15. Ueno NT, Bartholomeusz C, Herrmann JL, et al: E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 6: 250-259, 2000. (Pubitemid 30065000)
16. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
17. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
18. Chuang TC, Hsu SC, Cheng YT, Shao WS, Wu K, Fang GS, Ou CC and Wang V: Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells. Cancer Lett 311: 11-19, 2011.
19. Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M and Fujimoto-Ouchi K: Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 17: 5060-5070, 2011.
20. Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K and Nakagawa K: Roles of BIM induction and survivin down-regulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Oncogene 30: 4097-4106, 2011.
21. Decock J, Thirkettle S, Wagstaff L and Edwards DR: Matrix metallo proteinases: protective roles in cancer. J Cell Mol Med 15: 1254-1265, 2011.
22. Hua H, Li M, Luo T, Yin Y and Jiang Y: Matrix metallo-proteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 68: 3853-3868, 2011.
23. Luukkaa H, Klemi P, Leivo I, et al: Expression of matrix metalloproteinase-1, -7, -9, -13, Ki-67, and HER-2 in epithelial-myoepithelial salivary gland cancer. Head Neck 32: 1019-1027, 2010.
24. Kim IY, Yong HY, Kang KW and Moon A: Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9. Cancer Lett 275: 227-233, 2009.
25. Tan M, Yao J and Yu D: Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57: 1199-1205, 1997. (Pubitemid 27138623)
26. Chua KN, Poon KL, Lim J, Sim WJ, Huang RY and Thiery JP: Target cell movement in tumor and cardiovascular diseases based on the epithelial- mesenchymal transition concept. Adv Drug Deliv Rev 63: 558-567, 2011.
27. Sethi S, Sarkar FH, Ahmed Q, et al: Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol 4: 222-226, 2011.
28. Jenndahl LE, Isakson P and Baeckström D: c-erbB2-induced epithelial-mesenchymal transition in mammary epithelial cells is suppressed by cell-cell contact and initiated prior to E-cadherin downregulation. Int J Oncol 27: 439-448, 2005.
29. Ricono JM, Huang M, Barnes LA, et al: Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res 69: 1383-1391, 2009.
30. Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S and Auersperg N: Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol 290: C1532-C1542, 2006. (Pubitemid 43830793)
31. Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M and Tanabe KK: Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 68: 2391-2399, 2008. (Pubitemid 351521814)
32. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
33. Vergara D, Merlot B, Lucot J P, Collinet P, Vinatier D, Fournier I and Salzet M: Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 291: 59-66, 2010.
34. Lu YM, Zhang SL, Meng LR and Zhao YY: Influence of human epidermal growth factor receptor-2 siRNA on chemosensitivity to cisplatin of human ovarian carcinoma cells: an in vitro experiment. Zhonghua Yi Xue Za Zhi 88: 909-913, 2008 (In Chinese).
35. Abuharbeid S, Apel J, Zugmaier G, et al: Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol 371: 141-151, 2005. (Pubitemid 40487419)